Tuesday, June 22
Shadow

Nebraska Medicine, UNMC need 1,000 volunteers for COVID-19 vaccine study – KETV Omaha

Novavax is currently in Phase 3 studies to evaluate the effectiveness of its COVID-19 vaccine. Nebraska Medicine and UNMC are part of those studies and are looking for people to participate. Up to 1,000 people can participate in the study at UNMC. Within the next few months, participants will be administered a placebo shot or the Novavax COVID-19 vaccine. “The randomization scheme is weighted so that about two-thirds of the people will get the active vaccine and the third will get the placebo,” Dr. Mark Rupp said. Rupp said the Novavax trail will be studied just like previous COVID-19 vaccine trials. “Will one vaccine be better for treating elderly people or immunosuppressed people? Will one have a longer-lasting level of immunity those are the things we’re looking for as we test these new types of vaccines,” Rupp said. It’s a Phase 3 trial. UNMC and Nebraska Medicine are just one of over 100 centers involved. Researchers will look into the effectiveness of the latest vaccine. Rupp said the U.S. needs more COVID-19 vaccine options. “There will not be enough of the Moderna and Pfizer vaccines to go around for every citizen in the United States,” Rupp said. Rupp said participating in the trial could benefit people looking to get vaccinated sooner than the general population. “I think it’s an attractive option for people who are lower down the list of prioritization for the vaccines that are under emergency-use authorization,” Rupp said. Leading the study is Dr. Diana Florescu. “We also want to involve the most vulnerable communities: minorities, people over the age of 65, and those with other health conditions,” Florescu said. Novavax is also follow suit with a two-shot vaccine. It will be administered about three weeks apart. To sign-up for the vaccine trial click, here.

Novavax is currently in Phase 3 studies to evaluate the effectiveness of its COVID-19 vaccine. Nebraska Medicine and UNMC are part of those studies and are looking for people to participate.

Up to 1,000 people can participate in the study at UNMC. Within the next few months, participants will be administered a placebo shot or the Novavax COVID-19 vaccine.

“The randomization scheme is weighted so that about two-thirds of the people will get the active vaccine and the third will get the placebo,” Dr. Mark Rupp said.

Rupp said the Novavax trail will be studied just like previous COVID-19 vaccine trials.

“Will one vaccine be better for treating elderly people or immunosuppressed people? Will one have a longer-lasting level of immunity those are the things we’re looking for as we test these new types of vaccines,” Rupp said.

It’s a Phase 3 trial. UNMC and Nebraska Medicine are just one of over 100 centers involved. Researchers will look into the effectiveness of the latest vaccine. Rupp said the U.S. needs more COVID-19 vaccine options.

“There will not be enough of the Moderna and Pfizer vaccines to go around for every citizen in the United States,” Rupp said.

Rupp said participating in the trial could benefit people looking to get vaccinated sooner than the general population.

“I think it’s an attractive option for people who are lower down the list of prioritization for the vaccines that are under emergency-use authorization,” Rupp said.

Leading the study is Dr. Diana Florescu.

“We also want to involve the most vulnerable communities: minorities, people over the age of 65, and those with other health conditions,” Florescu said.

Novavax is also follow suit with a two-shot vaccine. It will be administered about three weeks apart. To sign-up for the vaccine trial click, here.

Leave a Reply

Your email address will not be published. Required fields are marked *